Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study
| Autor: | Elżbieta Papuga-Szela, Anna Weronska, Anetta Undas, Elżbieta Broniatowska |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Pyridones Deep vein Administration Oral Hemorrhage Risk Assessment Antithrombins Dabigatran Polycythemia vera Rivaroxaban Recurrence Risk Factors Interquartile range Internal medicine Secondary Prevention medicine Humans Polycythemia Vera Aged Pharmacology Essential thrombocythemia business.industry Venous Thromboembolism Middle Aged medicine.disease Thrombosis Treatment Outcome medicine.anatomical_structure Pyrazoles Female Apixaban Cardiology and Cardiovascular Medicine business Factor Xa Inhibitors Thrombocythemia Essential medicine.drug |
| Zdroj: | Journal of Cardiovascular Pharmacology. 78:e743-e748 |
| ISSN: | 0160-2446 |
| Popis: | Thrombosis is the most common adverse event in patients with polycythemia vera (PV) and essential thrombocythemia (ET). Little is known about the use of nonvitamin K antagonist oral anticoagulants (NOACs) in patients with myeloproliferative neoplasms. We sought to evaluate the efficacy and safety of NOAC in a cohort of patients with PV and ET, who experienced venous thromboembolism (VTE). We enrolled 48 consecutive patients with PV (70.8%) and ET [median age 67.0 (interquartile range, 58.5-72.0) years], who experienced VTE. Patients received apixaban (39.6%), rivaroxaban (33.3%), or dabigatran (27.1%). During a median follow-up of 30 (interquartile range, 20.5-41.5) months, recurrent thrombotic events and bleeding were recorded. Four thrombotic events (3.3 per 100 patient-years) were reported. Three deep vein thrombosis episodes (2.5 per 100 patient-years) were experienced by 2 patients with PV, who received apixaban (5 mg bid) and dabigatran (150 mg bid), and 1 patient with ET, who received dabigatran (150 mg bid). One ischemic stroke occurred in a patient with PV on rivaroxaban (20 mg/d). There was 1 major bleeding (0.8 per 100 patient-years) in a patient with ET on dabigatran (150 mg bid) and 3 clinically relevant nonmajor bleeding (2.5 per 100 patient-years): 2 on rivaroxaban (20 mg/d) and 1 on apixaban (5 mg bid). We did not observe significant differences related to the type of NOAC. Three deaths (2.5 per 100 patient-years) unrelated to either VTE or bleeding were recorded. This study shows that NOACs may be effective and safe as secondary prevention of VTE in patients with myeloproliferative neoplasms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|